Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025CancersOpen Access

The Utility of Immune Checkpoint Inhibition in the Management of Resectable Non-Small Cell Lung Cancer

View Full Paper
Ask AI
Bookmark
Share

Authors

LFLouis FilipiakKPKoosha PaydaryMFMary J. Fidler

Discussion

Loading...

Member takes

Overview

This review demonstrates the role of immune checkpoint inhibitors in resectable NSCLC, suggesting potential survival benefits.

Key Points

  • Immune checkpoint inhibitors improved survival for some patients with advanced non-small cell lung cancer.
  • Adjuvant and neoadjuvant therapies in resectable NSCLC may lead to higher cure rates.
  • Clinical trials provide critical insights into the efficacy of immune checkpoint inhibitors in patients with resectable lung cancers.
  • Current literature shows no level 1 evidence for choosing neoadjuvant versus perioperative approaches.

Cite This Study

Filipiak et al. (2025) studied this question.

synapsesocial.com/papers/68c2409bb210217d6479b766https://doi.org/10.3390/cancers17152462
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Immune checkpoint inhibitors as neoadjuvant therapy for resectable non-small cell lung cancer: a systematic review and network meta-analysis2025
  2. 2The role of immunotherapy in resectable non-small-cell lung cancer2025
  3. 3Neoadjuvant therapy of NSCLC: a review of the use and impact of monoclonal antibodies2025
  4. 4A Real‐World Study of Resectable <scp>NSCLC</scp> Following Neoadjuvant Immunotherapy: Should Postoperative Adjuvant Immunotherapy be Recommended?2025 · 2 citations
  5. 5Chemoimmunotherapy for Patients with Resectable Non-Small Cell Lung Carcinoma: Real-World Data Analysis from a Surgical Point of View2025